AARD at a glance
Aardvark Therapeutics, Inc. (AARD, SEC CIK 1774857) filed its latest 10-K annual report on March 23, 2026, a 10-Q quarterly report on November 13, 2026, an 8-K current report on November 13, 2026 and Form 4 insider filings as recently as November 10, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Aardvark Therapeutics, Inc. (AARD) reported revenue of $0 (down 100.0% from FY2024) and a net loss of $57.6 million. Diluted EPS was -$2.93.
- As of September 30, 2026, 16 institutional investment managers tracked by SignalX reported holding Aardvark Therapeutics, Inc. (AARD) shares worth $12.1 million in 13F-HR filings.
- In the last 90 days, AARD insiders reported 0 open-market purchases ($0) and 2 open-market sales ($395K) on Form 4, a net sale of $395K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $0
- −100.0% vs prior year
- Insiders · 90 days
- 0 buys · 2 sells
- Net −$395K
- 13F holders
- 16 funds
- $12.1M · +1 vs prior quarter
- Latest 8-K
- Nov 13, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no products approved for sale
- Net loss $19.2M vs $16.3M YoY, operating loss $19.7M vs $17.7M
- R&D expense $15.7M vs $13.7M, worst-performing line, driven by cardiac safety studies
- Cash, equivalents and short-term investments $60.3M at September 30, 2026, funding projected through 2027
- FDA clinical hold lifted in October 2026, ARD-201 development paused, FDA meeting scheduled for first quarter 2027
Risk Factors
- New regulatory risk triggered by October 2026 FDA clinical-hold lifting: no alignment yet on ARD-101 Phase 3 design, dose, or additional studies
- Most material update: cardiac safety findings led to HERO and OLE termination after 67 participants, despite FDA attribution of serious event to pitolisant interaction
- Near-term clinical risk: exploratory HERO and OLE data may not support future development, with HERO terminated before planned 90 participants
- Financial risk: $60.3 million cash, cash equivalents and short-term investments expected to fund operations through 2027, but new Phase 3 requires additional funding
- Market risk: PWS’s limited patient pool may delay enrollment, especially after prior clinical pauses and ARD-101 clinical hold
AI summary of the AARD 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results for quarter ended September 30, 2026
- Business updates included in November 13, 2026 press release
Item EX-99.1: Item EX-99.1
- FDA lifted ARD-101’s PWS clinical hold, enabling an open-label trial at 200 mg twice daily
- FDA meeting scheduled for Q1 2027, with PWS clinical activities expected to resume in 2027 subject to alignment
Item 8.01: Other Events
- Exploratory efficacy data released from terminated Phase 3 HERO and OLE trials
- Investor webinar held October 23, 2026 at 8:00 a.m. ET
Item EX-99.1: Item EX-99.1
- HERO trial stopped early with 67 of 90 planned participants, making all efficacy results exploratory
- OLE participants switching from placebo to ARD-101 showed average HQ-CT reduction of 6 points by Day 28
Item EX-99.2: Item EX-99.2
- FDA clinical hold lifted in October 2026, allowing Aardvark to resume ARD-101 development for Prader-Willi syndrome
- HERO enrollment truncated at 67 participants versus planned 90, making efficacy results exploratory rather than confirmatory
Item 8.01: Other Events
- FDA lifted the clinical hold on ARD-101’s Investigational New Drug application
- Regulatory clearance enables clinical development for hyperphagia in Prader-Willi Syndrome
Item EX-99.1: Item EX-99.1
- FDA lifted the clinical hold on ARD-101, reopening a path for Prader-Willi Syndrome development
- Prior hold followed reversible ECG changes, creating a key cardiac-safety overhang for investors
AI summaries of AARD 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for AARD
Don't miss the next AARD filing
- Alerts as it files. A push when AARD files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut AARD, by share count.
- Ask anything. An AI agent that reads every AARD filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Lee Tien-Li | A | Nov 6, 2026 | 549,534 | - |
| Sun Nelson | D | Nov 6, 2026 | 23,719 | - |
| Lee Tien-Li | D | Nov 6, 2026 | 203,851 | - |
| Sun Nelson | D | Nov 6, 2026 | 209,826 | - |
| Sun Nelson | D | Nov 6, 2026 | 70,549 | - |
| Sun Nelson | A | Nov 6, 2026 | 23,719 | - |
| Lee Tien-Li | A | Nov 6, 2026 | 203,851 | - |
| Sun Nelson | A | Nov 6, 2026 | 70,549 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $2.4M | $0 |
| Operating Income | - | -$22.8M | -$62.7M |
| Net Income | - | -$20.6M | -$57.6M |
| Op. Margin | - | -943.9% | - |
| Net Margin | - | -852.9% | - |
| Balance Sheet | |||
| Total Assets | - | $77.5M | $117.2M |
| Equity | -$34.8M | -$54.6M | $106.6M |
| ROE | - | 37.7% | -54.0% |
| Per Share | |||
| EPS | - | $-5.15 | $-2.93 |
| Cash Flow | |||
| Operating CF | - | -$18.1M | -$54.2M |
| CapEx | - | $109K | $95K |
Source: XBRL data in Aardvark Therapeutics, Inc. (AARD)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate AARD share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 16 | $12.1M |
| Q2 2026 | 15 | $17.0M |
| Q1 2026 | 20 | $13.5M |
| Q4 2025 | 15 | $50.6M |
| Q3 2025 | 16 | $38.5M |
| Q2 2025 | 11 | $28.1M |
| Q1 2025 | 9 | $11.6M |
- Two Sigma Investments+21.2K (+20%)
- Raymond James Financial+13.6K (+17%)
- BlackRock+7.6K (+4%)
- AQR Capital Management−366.2K (-76%)
- Citadel Advisors LLC−308.1K (-24%)
- Citigroup−25.7K (-98%)
- Morgan Stanley−22.7K (-75%)
- Millennium Management−7.5K (-11%)
- D.E. Shaw & Co+40.6K
- Dimensional Fund Advisors+17.7K
- FMR LLC (Fidelity)−18.9K
Source: 13F-HR filings on SEC EDGAR (aggregated from 102 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
AARD filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 13, 2026 | - | Analysis | - |
| 10-Q | Nov 13, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Nov 10, 2026 | - | - | - |
| 4 | Nov 10, 2026 | - | - | - |
| 4 | Nov 10, 2026 | - | - | - |
| 8-K | Oct 23, 2026 | - | Analysis | - |
| 8-K | Oct 22, 2026 | - | Analysis | - |
| 8-K | Oct 8, 2026 | - | Analysis | - |
| 4 | Oct 8, 2026 | - | - | - |
| 4 | Sep 11, 2026 | - | - | - |
| 4 | Aug 21, 2026 | - | - | - |
| 4 | Aug 21, 2026 | - | - | - |
| 4 | Aug 21, 2026 | - | - | - |
| 4 | Aug 21, 2026 | - | - | - |
| 8-K | Aug 17, 2026 | - | Analysis | - |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 10-Q | Aug 11, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jun 12, 2026 | - | Analysis | - |
| 8-K | May 14, 2026 | - | Analysis | |
| 8-K | May 7, 2026 | - | Analysis | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Mar 24, 2026 | - | - | - |
| 10-K | Mar 23, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 23, 2026 | - | - | - |
| 8-K | Feb 27, 2026 | - | Analysis | - |
Related Health Care companies
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
- ACET · Adicet Bio IncPharmaceutical Preparations
AARD SEC filings: frequently asked questions
Are AARD insiders buying or selling?
In the last 90 days, Aardvark Therapeutics, Inc. (AARD) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $394,957 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold AARD stock?
As of September 30, 2026, the largest Aardvark Therapeutics, Inc. (AARD) holders among the 13F filers tracked by SignalX were Citadel Advisors LLC ($5.1 million), Vanguard Capital Management LLC ($2.9 million), BlackRock ($1.0 million), Two Sigma Investments ($683,000), AQR Capital Management ($602,000). 13F-HR reports are filed up to 45 days after each quarter ends.
What was AARD's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Aardvark Therapeutics, Inc. (AARD) reported revenue of $0 (down 100.0% from FY2024) and a net loss of $57.6 million. Diluted EPS was -$2.93. The figures come from the XBRL data in the 10-K.
What did AARD report in its latest 8-K?
Aardvark Therapeutics, Inc. (AARD) filed an 8-K on November 13, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results for quarter ended September 30, 2026.
What are the latest AARD SEC filings?
Aardvark Therapeutics, Inc. (AARD) filed its latest 10-K annual report on March 23, 2026, a 10-Q quarterly report on November 13, 2026, an 8-K current report on November 13, 2026 and a Form 4 insider filing on November 10, 2026.
What is AARD's SEC CIK number?
Aardvark Therapeutics, Inc. (AARD)'s SEC Central Index Key (CIK) is 1774857. EDGAR lists every AARD filing under that number.
Ask anything about AARD
The research agent reads AARD's filings, financials, insider trades and 13F holders, then answers with sources.